AR089483A1 - Compuestos dimeros agonistas de los receptores de los fgf (fgfr), su proceso de preparacion y su aplicacion en terapeutica - Google Patents

Compuestos dimeros agonistas de los receptores de los fgf (fgfr), su proceso de preparacion y su aplicacion en terapeutica

Info

Publication number
AR089483A1
AR089483A1 ARP120105003A ARP120105003A AR089483A1 AR 089483 A1 AR089483 A1 AR 089483A1 AR P120105003 A ARP120105003 A AR P120105003A AR P120105003 A ARP120105003 A AR P120105003A AR 089483 A1 AR089483 A1 AR 089483A1
Authority
AR
Argentina
Prior art keywords
group
monomer unit
oxygen atom
alkyl group
binding site
Prior art date
Application number
ARP120105003A
Other languages
English (en)
Inventor
Benazet Alexandre
Guillo Nathalie
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR089483A1 publication Critical patent/AR089483A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Su aplicación terapéutica comprende enfermedades cardiovasculares y neuronales. Reivindicación 1: Compuestos agonistas de los receptores de los FGF que responden a la fórmula general (1): M¹-L-M² (1) en la que M¹ y M² idénticos o diferentes representan cada uno independientemente entre sí una unidad monómera M y L representa un grupo de unión que une M¹ y M² de forma covalente, caracterizados por que dicha unidad monómera M responde a la fórmula general (2) en la que, * indica que el sitio de unión entre la unidad monómera M y el ligante L; R¹ representa un grupo -NHCOPh, estando dicho fenilo sustituido con un átomo de oxígeno, tal que el átomo de oxígeno es el sitio de unión entre la unidad monómera y el ligante L, se puede apreciar este grupo -NHCOPhO*, o un grupo arilo, en particular fenilo, o heteroarilo, estando dicho grupo sustituido con un grupo elegido entre un átomo de oxígeno divalente, tal que el átomo de oxígeno es el sitio de unión entre la unidad monómera y el ligante L, o un grupo amida -CONH* tal que el átomo de nitrógeno es el sitio de unión entre la unidad monómera y el ligante L; R² representa un grupo alquilo; R³ representa un átomo de hidrógeno, o un grupo alquilo lineal o ramificado, cíclico o parcialmente cíclico; R⁴ representa un átomo de hidrógeno o un grupo alquilo, -alquilo-COOR⁵ con R⁵ representando un átomo de hidrógeno o un grupo alquilo; en forma de base o de sal de adición a un ácido o a una base.
ARP120105003A 2011-12-28 2012-12-27 Compuestos dimeros agonistas de los receptores de los fgf (fgfr), su proceso de preparacion y su aplicacion en terapeutica AR089483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1162486A FR2985258A1 (fr) 2011-12-28 2011-12-28 Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR089483A1 true AR089483A1 (es) 2014-08-27

Family

ID=47716120

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120105003A AR089483A1 (es) 2011-12-28 2012-12-27 Compuestos dimeros agonistas de los receptores de los fgf (fgfr), su proceso de preparacion y su aplicacion en terapeutica

Country Status (27)

Country Link
US (1) US9206177B2 (es)
EP (1) EP2797930B1 (es)
JP (1) JP6049755B2 (es)
KR (1) KR20140114375A (es)
CN (1) CN104136444B (es)
AR (1) AR089483A1 (es)
AU (1) AU2012360094B9 (es)
BR (1) BR112014016126A8 (es)
CA (1) CA2861741C (es)
CY (1) CY1118997T1 (es)
DK (1) DK2797930T3 (es)
ES (1) ES2598083T3 (es)
FR (1) FR2985258A1 (es)
HK (1) HK1198648A1 (es)
HR (1) HRP20161306T1 (es)
HU (1) HUE029036T2 (es)
IL (1) IL233325A0 (es)
LT (1) LT2797930T (es)
MX (1) MX356658B (es)
PL (1) PL2797930T3 (es)
PT (1) PT2797930T (es)
RU (1) RU2014131014A (es)
SG (2) SG11201403571QA (es)
SI (1) SI2797930T1 (es)
TW (1) TWI582093B (es)
UY (1) UY34560A (es)
WO (1) WO2013098763A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
ME02651B (me) 2012-06-13 2017-06-20 Incyte Holdings Corp Substituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2909207C (en) 2013-04-19 2021-11-02 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JP6854776B2 (ja) 2015-01-08 2021-04-07 インぺティス バイオサイエンス リミテッド 二環式化合物、その組成物および医薬用途
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR102409669B1 (ko) * 2020-11-10 2022-06-16 아주대학교산학협력단 인돌리진 유도체 화합물 및 이를 포함하는 표적 물질 검출용 화합물
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
EP1583747A2 (en) * 2002-12-31 2005-10-12 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
LT2194783T (lt) * 2007-08-10 2017-10-25 Vm Discovery, Inc. Apoptozės moduliatorių kompozicijos ir būdai
EP2270043A1 (en) * 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
PL2797930T3 (pl) 2017-08-31
SI2797930T1 (sl) 2016-11-30
CN104136444A (zh) 2014-11-05
CA2861741C (en) 2019-09-17
US20140378483A1 (en) 2014-12-25
AU2012360094B9 (en) 2017-06-08
KR20140114375A (ko) 2014-09-26
WO2013098763A1 (en) 2013-07-04
JP6049755B2 (ja) 2016-12-21
HK1198648A1 (en) 2015-05-22
JP2015503545A (ja) 2015-02-02
MX2014007842A (es) 2014-11-25
TW201333007A (zh) 2013-08-16
BR112014016126A2 (pt) 2017-06-13
TWI582093B (zh) 2017-05-11
LT2797930T (lt) 2016-10-25
RU2014131014A (ru) 2016-02-20
SG10201609069YA (en) 2016-12-29
CN104136444B (zh) 2017-04-12
SG11201403571QA (en) 2014-07-30
FR2985258A1 (fr) 2013-07-05
IL233325A0 (en) 2014-08-31
UY34560A (es) 2013-07-31
AU2012360094A1 (en) 2014-07-24
HRP20161306T1 (hr) 2016-12-02
DK2797930T3 (en) 2016-11-07
CY1118997T1 (el) 2018-01-10
US9206177B2 (en) 2015-12-08
MX356658B (es) 2018-06-07
ES2598083T3 (es) 2017-01-25
HUE029036T2 (en) 2017-01-30
PT2797930T (pt) 2016-10-19
CA2861741A1 (en) 2013-07-04
EP2797930A1 (en) 2014-11-05
AU2012360094B2 (en) 2017-05-25
BR112014016126A8 (pt) 2017-07-04
EP2797930B1 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
AR089483A1 (es) Compuestos dimeros agonistas de los receptores de los fgf (fgfr), su proceso de preparacion y su aplicacion en terapeutica
AR089452A1 (es) Compuestos dimeros agonistas de los receptores de los fgf (fgfr), su procedimiento de preparacion y su aplicacion en terapeutica
AR118341A2 (es) Mezclas fungicidas ternarias
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
AR090868A1 (es) Composiciones plaguicidas y procesos relacionados con ellas
AR090967A1 (es) Picolinamidas macrociclicas como fungicidas
CO7111313A2 (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
AR088534A1 (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones
AR093767A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR094351A1 (es) Picolinamidas macrocíclicas como fungicidas
AR094168A1 (es) Composiciones pesticidas y procesos relacionados con ellas
RS54708B1 (en) ARYLETINYL DERIVATIVES
AR087624A1 (es) Derivados fenilicos y/o heterociclicos nitrogenados de sulfuro y sulfoxido utiles como pesticidas
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
CR20150661A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
RS54730B1 (sr) Inhibitori beta sekretaze
TR201907373T4 (tr) Tetrazolinon bileşiği ve bunun kullanımı.
WO2013076315A3 (en) Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
IN2014MN02211A (es)
AR097866A1 (es) Derivados de 4-azaindol
AR091770A1 (es) Indolcarbonitrilos moduladores selectivos de receptores androgenicos
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure